Precision molecule against Gram-negative infections: a new era of antibiotics that spare the gut microbiota
As Gram-negative bacterial infections rise, broad-spectrum antibiotics often disrupt the gut microbiome, leading to secondary infections. A new study introduces lolamicin, a Gram-negative-selective antibiotic targeting the Lol lipoprotein transport system, effectively preserving the gut microbiome and preventing secondary infections.
Sources
This article is based on scientific information
![](/sites/default/files/styles/image_1110x465/public/2024-09/11523997_HiRes_Klebsiella_pneumoniae_bacteria.jpg.webp?itok=vD2z7Pkc)
About this article
Author
Infections caused by (sidenote: Gram-negative bacteria A group of bacteria characterized by their unique cell wall structure, which makes them resistant to many antibiotics and often more challenging to treat. ) are becoming more common and are often treated with broad-spectrum antibiotics, which can disrupt the gut microbiome and lead to secondary infections. There is a pressing need for antibiotics that are selective for pathogenic Gram-negative bacteria while sparing commensal bacteria and the gut microbiome.
This new study 1 aimed to design and discover a Gram-negative-selective antibiotic that targets the Lol lipoprotein transport system, thereby preserving the gut microbiome and preventing secondary infections.
The Lol lipoprotein transport system is a vital mechanism in Gram-negative bacteria, essential for transporting lipoproteins to the outer membrane, where they perform crucial structural and functional roles. Its specificity to Gram-negative bacteria and its critical nature makes it an attractive target for antibiotic development.
Crafting a selective antibiotic
The development process began with a series of whole-cell screens at AstraZeneca, identifying compounds that inhibit the LolCDE complex, a critical component of the Lol system. Researchers prioritized compounds that showed initial promise but faced challenges in solubility and resistance. Through an iterative chemical modification process, they engineered a hybrid scaffold, appending primary amines to enhance compound accumulation and targeting efficiency.
The culmination of these efforts was the identification of (sidenote: Lolamicin A newly developed Gram-negative-selective antibiotic that targets the Lol lipoprotein transport system, effectively killing pathogenic bacteria without disrupting the gut microbiome. ) , a compound that effectively disrupts the Lol system, thereby selectively killing pathogenic Gram-negative bacteria. This selective targeting is made possible by the significant sequence homology divergence between pathogenic bacteria and commensal gut bacteria, ensuring that beneficial bacteria remain unharmed.
Achieving breakthrough results in infection models
The efficacy of lolamicin was put to the test in rigorous preclinical studies, and the results were nothing short of groundbreaking. Lolamicin demonstrated potent activity against a diverse panel of over 130
(sidenote:
Multidrug-resistant
Describes bacteria that have developed resistance to multiple classes of antibiotics, making infections caused by these bacteria particularly difficult to treat.
)
clinical isolates of Gram-negative bacteria, including notorious pathogens such as E. coli, Klebsiella pneumoniae, and Enterobacter cloacae.
In mouse models of acute pneumonia and septicaemia, lolamicin showcased its superior therapeutic potential. Mice treated with lolamicin exhibited a two-log reduction in bacterial burden and remarkable survival rates, significantly outperforming existing comparator antibiotics.
One of the standout features of lolamicin is its microbiome-sparing capability. Unlike broad-spectrum antibiotics that wreak havoc on the gut microbiome, lolamicin treatment resulted in minimal changes to the gut microbial composition. This was evidenced by full-length 16S rRNA sequencing of fecal samples from treated mice, which showed that lolamicin preserved the diversity and richness of the gut microbiome. Remarkably, mice treated with lolamicin retained their ability to spontaneously clear Clostridioides difficile colonization, a common and severe complication associated with antibiotic use.
Conclusion
Although validation in human clinical trials is needed, this advancement not only addresses the immediate challenge of resistant infections but also heralds a new era of precision-targeted treatments that safeguard overall health.